These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31944090)

  • 1. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment.
    Chen PH; Hu J; Wu J; Huynh DT; Smith TJ; Pan S; Bisnett BJ; Smith AB; Lu A; Condon BM; Chi JT; Boyce M
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31944090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gigaxonin is required for intermediate filament transport.
    Renganathan B; Zewe JP; Cheng Y; Paumier JM; Kittisopikul M; Ridge KM; Opal P; Gelfand VI
    FASEB J; 2023 May; 37(5):e22886. PubMed ID: 37043392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
    Mahammad S; Murthy SN; Didonna A; Grin B; Israeli E; Perrot R; Bomont P; Julien JP; Kuczmarski E; Opal P; Goldman RD
    J Clin Invest; 2013 May; 123(5):1964-75. PubMed ID: 23585478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.
    Boizot A; Talmat-Amar Y; Morrogh D; Kuntz NL; Halbert C; Chabrol B; Houlden H; Stojkovic T; Schulman BA; Rautenstrauss B; Bomont P
    Acta Neuropathol Commun; 2014 Apr; 2():47. PubMed ID: 24758703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization.
    Nath B; Julien JP
    J Neurosci; 2023 May; 43(22):4174-4189. PubMed ID: 37137704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.
    Johnson-Kerner BL; Ahmad FS; Diaz AG; Greene JP; Gray SJ; Samulski RJ; Chung WK; Van Coster R; Maertens P; Noggle SA; Henderson CE; Wichterle H
    Hum Mol Genet; 2015 Mar; 24(5):1420-31. PubMed ID: 25398950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A.
    Nath B; Phaneuf D; Julien JP
    Neurotherapeutics; 2023 Jul; 20(4):1215-1228. PubMed ID: 37268847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.
    Johnson-Kerner BL; Garcia Diaz A; Ekins S; Wichterle H
    PLoS One; 2015; 10(10):e0140157. PubMed ID: 26460568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.
    Kang JJ; Liu IY; Wang MB; Srivatsan ES
    Hum Genet; 2016 Jul; 135(7):675-84. PubMed ID: 27023907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.
    Lin NH; Huang YS; Opal P; Goldman RD; Messing A; Perng MD
    Mol Biol Cell; 2016 Dec; 27(25):3980-3990. PubMed ID: 27798231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.
    Israeli E; Dryanovski DI; Schumacker PT; Chandel NS; Singer JD; Julien JP; Goldman RD; Opal P
    Hum Mol Genet; 2016 Jun; 25(11):2143-2157. PubMed ID: 27000625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.
    Mussche S; Devreese B; Nagabhushan Kalburgi S; Bachaboina L; Fox JC; Shih HJ; Van Coster R; Samulski RJ; Gray SJ
    Hum Gene Ther; 2013 Feb; 24(2):209-19. PubMed ID: 23316953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRL3
    Park HM; Le L; Nguyen TT; Nam KH; Ordureau A; Lee JE; Nguyen TV
    Proc Natl Acad Sci U S A; 2023 Nov; 120(45):e2306395120. PubMed ID: 37903270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis.
    Johnson-Kerner BL; Roth L; Greene JP; Wichterle H; Sproule DM
    Muscle Nerve; 2014 Oct; 50(4):467-76. PubMed ID: 24947478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1.
    Dequen F; Bomont P; Gowing G; Cleveland DW; Julien JP
    J Neurochem; 2008 Oct; 107(1):253-64. PubMed ID: 18680552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy.
    Arribat Y; Mysiak KS; Lescouzères L; Boizot A; Ruiz M; Rossel M; Bomont P
    J Clin Invest; 2019 Dec; 129(12):5312-5326. PubMed ID: 31503551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GlcNAc signaling in cancer metabolism and epigenetics.
    Singh JP; Zhang K; Wu J; Yang X
    Cancer Lett; 2015 Jan; 356(2 Pt A):244-50. PubMed ID: 24769077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of the Intermediate Filament Family by Gigaxonin.
    Bomont P
    Methods Enzymol; 2016; 569():215-31. PubMed ID: 26778561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant axonal neuropathy.
    Hentati F; Hentati E; Amouri R
    Handb Clin Neurol; 2013; 115():933-8. PubMed ID: 23931822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
    Lowery J; Jain N; Kuczmarski ER; Mahammad S; Goldman A; Gelfand VI; Opal P; Goldman RD
    Mol Biol Cell; 2016 Feb; 27(4):608-16. PubMed ID: 26700320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.